D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today ...
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback